Category: Include on Menu
-
Robinhood Falls 10% After Q1 Miss, Higher Expense Outlook Weighs
Robinhood Markets Inc. (NASDAQ:HOOD) reported first-quarter results that came in below expectations, with both earnings and revenue missing analyst forecasts. Shares dropped nearly 10% in premarket trading on Wednesday following the release. The company posted adjusted earnings per share of $0.38, falling short of the consensus estimate of $0.41. Revenue totaled $1.07 billion, also below…
-
Starbucks Gains After Upgrading Outlook as Turnaround Momentum Builds
Starbucks (NASDAQ:SBUX) lifted its full-year 2026 guidance on Tuesday, raising expectations for both comparable-store sales growth and adjusted earnings per share, as CEO Brian Niccol continues to push forward a turnaround strategy that is attracting more customers back to stores. The company now expects comparable store sales to grow by at least 5.0% in fiscal…
-
Oil Extends Rally on Reports of Prolonged U.S. Blockade on Iran
Oil prices climbed further on Wednesday, building on gains from recent sessions, after reports indicated the United States is preparing to extend its blockade of Iranian ports—raising the likelihood of continued supply disruptions across the Middle East. According to The Wall Street Journal, Donald Trump has directed aides to get ready for a prolonged blockade…
-
Gold Holds Near One-Month Low as Iran Tensions Persist; Fed Decision in Focus
Gold prices hovered close to a one-month low on Wednesday, as demand for the precious metal remained subdued amid ongoing uncertainty surrounding the conflict with Iran. Investor caution ahead of the latest Federal Reserve policy decision also added pressure. The metal has recorded notable losses this week, with safe-haven flows favoring the U.S. dollar instead.…
-
Markets Steady Ahead of Fed Decision and Key Tech Earnings: Dow Jones, S&P, Nasdaq, Wall Street Futures
U.S. equity futures were slightly higher on Wednesday but remained close to flat, as investors braced for a wave of major announcements that could influence market direction. The Federal Reserve is widely expected to leave interest rates unchanged, though reports suggest it may adopt a more hawkish tone in its policy statement. At the same…
-
This micro-cap stock is leading the US graphite revolution
In parts one and two of this three-part series, we laid the foundation for why graphite is one of the most important critical minerals of our time, with deep ties to the defense, technology and renewable energy industries, and why Graphite One (USOTC:GPHOF) (TSXV:GPH), owner and developer of the Graphite Creek deposit in Alaska, the largest graphite deposit in the…
-
OpenAI Revenue Concerns Drag Tech Stocks Lower, Offset Earnings Strength From GM and Coca-Cola
U.S. stocks closed lower on Tuesday as a leaked internal report from OpenAI rattled the artificial intelligence trade and sent semiconductor and cloud-infrastructure names sliding. The selloff was concentrated in technology, where fears about the sustainability of AI spending overwhelmed an otherwise solid batch of corporate earnings. Defensive pockets of the market held up better,…
-
LaFleur Minerals Expands Val-d’Or Footprint with Strategic Gold Acquisition and Strong Drill Results
LaFleur Minerals Inc (CSE:LFLR) (USOTC:LFLRF) is making a confident stride forward in its growth strategy with the acquisition of the McKenzie East Gold Project in the renowned Val-d’Or mining district of Québec. This move strengthens the company’s position in one of Canada’s most productive gold regions and underscores its commitment to building a scalable, district-wide…
-
Nomadar Adds NBA Veteran José Calderón to Board — Strategic Move to Boost Global Growth Narrative?
The appointment of a high-profile global athlete and investor could signal Nomadar’s push to strengthen institutional credibility and accelerate its European expansion strategy. NOMA Stock Gets Strategic Boost with High-Profile Board Appointment José Manuel Calderón is joining the Board of Nomadar Corp. (NASDAQ:NOMA), and for investors, this isn’t just a headline—it’s about positioning. The move…
-
SNGX Phase 3 Trial Halted on HyBryte
Key Investor Takeaways Soligenix (SNGX) announced its Phase 3 trial halted for futility after an interim analysis of its FLASH2 study evaluating HyBryte™ in cutaneous T-cell lymphoma (CTCL), a development that may materially impact the drug’s regulatory path and the company’s near-term outlook. Soligenix announced that the Data Monitoring Committee completed an interim efficacy analysis…